ArticleEuropean journal of nuclear medicine and molecular imaging2017
The potential of
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 78 citations in OpenAlex.
- Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.JNCI cancer spectrum · 2023Trial
- Whole-Body [Tomography (Ann Arbor, Mich.) · 2021Trial
- BaselineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Trial
- Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223.EJNMMI reports · 2026Article
- EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses.European journal of nuclear medicine and molecular imaging · 2025Review
- Joint Regional Uptake Quantification of Thorium-227 and Radium-223 Using a Multiple-Energy-Window Projection-Domain Quantitative SPECT Method.IEEE transactions on medical imaging · 2024Article
- ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.European radiology · 2024Article
- WIN-PDQ: A Wiener-estimator-based projection-domain quantitative SPECT method that accounts for intra-regional uptake heterogeneity.Proceedings of SPIE--the International Society for Optical Engineering · 2024Article
- A Projection-Domain Low-Count Quantitative SPECT Method forIEEE transactions on radiation and plasma medical sciences · 2023Article
- A Primer on Radiopharmaceutical Therapy.International journal of radiation oncology, biology, physics · 2023Review
- Milestones in dosimetry for nuclear medicine therapy.The British journal of radiology · 2022Review
- Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.Frontiers in medicine · 2022Review
- Plasma Circulating Tumor Epstein-Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma.Frontiers in oncology · 2022Article
- Why bother with alpha particles?European journal of nuclear medicine and molecular imaging · 2021Article
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
- Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.Future science OA · 2021Article
- Radiopharmacokinetic modelling and radiation dose assessment ofEJNMMI physics · 2021Article
- Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2021Review
- Sodium Fluoride-18 and Radium-223 Dichloride Uptake Colocalize in Osteoblastic Mouse Xenograft Tumors.Cancer biotherapy & radiopharmaceuticals · 2021Article
Corrections and comments
- Commented on byOn the2018
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
purposeThe aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of
methodsFive patients received two intravenous injections of
resultsAbsorbed doses to metastatic bone lesions ranged from 0.6 Gy to 44.1 Gy. For individual patients, there was an average factor difference of 5.3 (range 2.5-11.0) between the maximum and minimum lesion dose. A relationship between lesion-absorbed doses and serial changes in
conclusionsThere is both inter-patient and intra-patient heterogeneity of absorbed dose estimates to metastatic lesions. A relationship between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.